Baird Financial Group Inc. Sells 188,043 Shares of Pfizer Inc. $PFE

Key Points

• Baird Financial Group Inc. reduced its stake in Pfizer Inc. by 6.3%, selling 188,043 shares, and now holds a total of 2,801,571 shares worth approximately $70.99 million.
• Pfizer recently announced a quarterly dividend of $0.43, equating to an annualized dividend of $1.72 and a yield of 7.0%.
• Pfizer's most recent earnings report showed an EPS of $0.78—surpassing analyst expectations—and revenue of $14.65 billion, indicating a 10.3% increase compared to the previous year.

Baird Financial Group Inc. decreased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 6.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,801,571 shares of the biopharmaceutical company's stock after selling 188,043 shares during the quarter. Baird Financial Group Inc.'s holdings in Pfizer were worth $70,992,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock worth $13,257,004,000 after acquiring an additional 4,629,976 shares during the period. Northern Trust Corp lifted its stake in Pfizer by 6.8% in the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock worth $1,579,340,000 after acquiring an additional 3,943,397 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Pfizer by 3.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock worth $1,045,351,000 after acquiring an additional 1,333,740 shares during the period. Invesco Ltd. lifted its stake in Pfizer by 2.8% in the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock worth $767,709,000 after acquiring an additional 838,198 shares during the period. Finally, Deutsche Bank AG lifted its stake in Pfizer by 7.0% in the first quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock worth $715,581,000 after acquiring an additional 1,846,436 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of Pfizer stock opened at $24.74 on Friday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The business has a fifty day simple moving average of $24.79 and a two-hundred day simple moving average of $24.38. The firm has a market capitalization of $140.65 billion, a P/E ratio of 13.16, a P/E/G ratio of 0.88 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is currently 91.49%.

Wall Street Analyst Weigh In

A number of analysts recently commented on PFE shares. Berenberg Bank dropped their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Jefferies Financial Group raised their price target on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. HSBC lowered their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Finally, Bank of America raised their price objective on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.